Ribosomes are tiny molecular machines inside your cells that build proteins. Every cell in your body contains millions of them, with a typical human cell housing roughly 3.3 million ribosomes. They read genetic instructions carried from your DNA and use those instructions to assemble proteins one amino acid at a time, a process called translation.
How Ribosomes Are Built
Each ribosome is made of two components: ribosomal RNA (rRNA) and proteins. The RNA isn’t just structural scaffolding. It’s the part that actually does the chemical work of linking amino acids together, making the ribosome one of biology’s best examples of a “ribozyme,” a molecule where RNA acts as a catalyst. Proteins make up about a third of the ribosome’s mass, while RNA accounts for the rest.
Ribosomes are assembled in a specialized region of the cell nucleus called the nucleolus. There, a large precursor RNA molecule is transcribed and then cut into three separate rRNA pieces. These pieces combine with ribosomal proteins to form two unequal halves: a small subunit and a large subunit. The two halves are exported separately from the nucleus into the cell’s cytoplasm, where they come together on a strand of messenger RNA to begin building a protein.
How Ribosomes Build Proteins
The ribosome works like a reading head on a tape. It moves along a messenger RNA strand, reading the genetic code three letters at a time. Each three-letter “codon” specifies one amino acid. Transfer RNA molecules ferry the correct amino acids to the ribosome, which links them into a growing chain.
This happens at three internal docking stations called the A, P, and E sites. A new amino acid arrives at the A site, carried by its transfer RNA. The growing protein chain sits at the P site. When the ribosome catalyzes a bond between the chain and the new amino acid, the chain shifts to the A site. Then the whole assembly advances one codon: the now-empty transfer RNA slides to the E (exit) site and leaves, the chain moves to the P site, and the A site opens for the next amino acid. This cycle repeats hundreds or thousands of times until the ribosome reaches a stop signal on the messenger RNA and releases the finished protein.
Crystal structures of the ribosome’s core confirm that the bond-forming region is composed entirely of RNA, with no protein anywhere near the active site. The RNA positions the two reacting molecules precisely and may also chemically boost the reaction rate. Mutating a single RNA building block at the catalytic center slows protein assembly by about 100-fold.
Prokaryotic vs. Eukaryotic Ribosomes
All living cells use ribosomes, but they come in two size classes. Bacterial (prokaryotic) ribosomes are smaller, designated 70S, with a 30S small subunit and a 50S large subunit. Human and other eukaryotic ribosomes are larger at 80S, split into a 40S small subunit and a 60S large subunit. (The “S” stands for Svedberg units, a measure of how fast a particle settles in a centrifuge. The numbers don’t add up neatly because the measurement depends on shape, not just mass.)
Despite performing the same basic job, the two types differ in how they interact with messenger RNA. Bacterial small subunits can latch onto messenger RNA on their own, while eukaryotic small subunits need a transfer RNA already present to do so. These structural and behavioral differences are medically important, because drugs can be designed to shut down bacterial ribosomes without affecting human ones.
Free and Membrane-Bound Ribosomes
Inside a eukaryotic cell, ribosomes work in two locations. Free ribosomes float in the cytoplasm and produce proteins destined to stay inside the cell, including those shipped to the nucleus, mitochondria, or peroxisomes. Membrane-bound ribosomes are attached to the surface of the endoplasmic reticulum, the network of folded membranes near the nucleus. These produce proteins that will be secreted from the cell or embedded in its outer membrane, as well as proteins headed for the cell’s internal compartments like lysosomes. The ribosomes themselves are identical in both locations. What determines where they end up is a signal sequence at the beginning of the protein they’re making, which either directs the ribosome to dock with the endoplasmic reticulum or lets it remain free.
Why Ribosomes Matter for Antibiotics
The structural differences between bacterial and human ribosomes are one of medicine’s most useful targets. Several major classes of antibiotics work by jamming bacterial ribosomes at specific points in the protein-building cycle.
- Tetracyclines bind to the small (30S) subunit’s A site, physically blocking new amino acid carriers from docking. Without fresh amino acids arriving, protein synthesis stalls.
- Macrolides (like erythromycin and its derivatives) plug the exit tunnel in the large (50S) subunit. The ribosome can still form a few peptide bonds, but the growing protein chain has nowhere to go, so production halts.
Many other antibiotic classes also cluster around the large subunit’s catalytic center or exit tunnel. Because human ribosomes differ enough in structure at these sites, the drugs bind selectively to bacterial versions, which is why you can take an antibiotic without shutting down protein production in your own cells.
Diseases Caused by Ribosome Defects
When ribosome assembly or function goes wrong in human cells, the consequences can be severe. A group of conditions called ribosomopathies arise from genetic mutations that impair ribosome production. These diseases disproportionately affect blood cell formation, likely because blood-producing cells in the bone marrow divide rapidly and have an especially high demand for new ribosomes.
Diamond-Blackfan anemia is the best-known example. It’s caused by mutations in genes encoding ribosomal proteins (most commonly one called RPS19), leading to a shortage of red blood cells and abnormally large red blood cells in those that do form. Other ribosomopathies include Shwachman-Diamond syndrome, which affects the pancreas and bone marrow; dyskeratosis congenita, which causes premature aging of tissues like the skin, nails, and oral lining; cartilage hair hypoplasia, which leads to short stature and immune deficiency; and Treacher Collins syndrome, which affects facial bone development.
Even acquired mutations can cause problems. The 5q- syndrome, a type of bone marrow disorder, results from a deletion on chromosome 5 that reduces levels of the ribosomal protein RPS14. The resulting blood abnormalities closely mirror those of Diamond-Blackfan anemia, reinforcing how sensitive cells are to even modest disruptions in ribosome supply.